Suppr超能文献

恩格列净对合并稳定型冠状动脉疾病的糖尿病患者循环内皮祖细胞的影响。

The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease.

机构信息

Department of Cardiology, Rabin Medical Center, 39 Jabotinsky St., 49100, Petah Tikva, Israel.

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Cardiovasc Diabetol. 2024 Oct 28;23(1):386. doi: 10.1186/s12933-024-02466-x.

Abstract

BACKGROUND

Diabetes mellitus (DM) is associated with premature atherosclerotic disease, coronary artery disease (CAD) and chronic heart failure (HF), leading to increased morbidity and mortality. Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) exhibit cardioprotective benefits beyond glucose lowering, reducing the risk of major cardiovascular events (MACE) and HF hospitalizations in patients with DM and CAD. Endothelial progenitor cells (EPCs) are bone marrow-derived cells involved in vascular repair, mobilized in response to vascular injury. The number and function of circulating EPCs (cEPCs) are negatively affected by cardiovascular risk factors, including DM. This study aimed to examine the response of cEPCs to SGLT2i treatment in DM patients with stable CAD.

METHODS

A prospective single-center study included patients with DM and stable CAD who were started on an SGLT2i (empagliflozin). Peripheral blood samples were collected at baseline, 1 month, and 3 months to evaluate cEPC levels and function by flow cytometry, immunohistochemistry and MTT assays.

RESULTS

Eighteen patients were included in the study (median age 73, (IQR 69, 77) years, 67% male). After 1 month of treatment with empagliflozin, there was no significant change in cEPCs level or function. However, following 3 months of treatment, a significant increase was observed both in cell levels (CD34(+)/VEGFR-2(+): from 0.49% (IQR 0.32, 0.64) to 1.58% (IQR 0.93, 1.82), p = 0.0006; CD133(+)/VEGFR-2(+): from 0.38% (IQR 0.27, 0.6) to 0.82% (IQR 0.7, 1.95), p = 0.0001) and in cell function (from 0.25 CFUs (IQR 0, 0.5) at baseline, to 2 CFUs (IQR 1, 2) at 3 months, p = 0.0012).

CONCLUSIONS

Empagliflozin treatment in patients with DM and stable CAD increases cEPC levels and function, implying a cardioprotective mechanism. These findings highlight the potential of SGLT2i in treating cardiovascular diseases, warranting further research to explore these effects and their long-term implications.

摘要

背景

糖尿病(DM)与动脉粥样硬化疾病、冠心病(CAD)和慢性心力衰竭(HF)的过早发生有关,导致发病率和死亡率增加。钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)在降低血糖之外具有心脏保护作用,可降低糖尿病和 CAD 患者的主要心血管事件(MACE)和 HF 住院风险。内皮祖细胞(EPCs)是参与血管修复的骨髓源性细胞,在血管损伤时被动员。循环内皮祖细胞(cEPCs)的数量和功能受到心血管危险因素的负面影响,包括 DM。本研究旨在探讨 SGLT2i 治疗稳定型 CAD 糖尿病患者时 cEPC 的反应。

方法

前瞻性单中心研究纳入了开始使用 SGLT2i(恩格列净)的 DM 合并稳定型 CAD 患者。在基线、1 个月和 3 个月时采集外周血样本,通过流式细胞术、免疫组织化学和 MTT 检测评估 cEPC 水平和功能。

结果

本研究纳入了 18 名患者(中位年龄 73 岁(IQR 69, 77)岁,67%为男性)。恩格列净治疗 1 个月后,cEPC 水平或功能无显著变化。然而,治疗 3 个月后,cEPC 细胞水平(CD34(+)/VEGFR-2(+):从 0.49%(IQR 0.32, 0.64)增加到 1.58%(IQR 0.93, 1.82),p=0.0006;CD133(+)/VEGFR-2(+):从 0.38%(IQR 0.27, 0.6)增加到 0.82%(IQR 0.7, 1.95),p=0.0001)和细胞功能(从基线时的 0.25 CFUs(IQR 0, 0.5)增加到 3 个月时的 2 CFUs(IQR 1, 2),p=0.0012)均显著增加。

结论

在稳定型 CAD 糖尿病患者中,恩格列净治疗可增加 cEPC 水平和功能,提示其具有心脏保护作用。这些发现强调了 SGLT2i 治疗心血管疾病的潜力,需要进一步研究来探索这些作用及其长期影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d46/11520434/c719ac694f02/12933_2024_2466_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验